62595-74-8

Usage

Uses

Used in Organic Synthesis:
3-Bromopiperidine-2,6-dione is used as a synthetic intermediate for the preparation of various organic compounds. Its reactivity, particularly the bromine atom, allows for versatile chemical transformations, making it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-bromopiperidine-2,6-dione is used as a key component in the development of new drugs. Its unique structure and reactivity enable the creation of novel therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Material Development:
3-Bromopiperidine-2,6-dione also has potential applications in the development of new materials. Its chemical properties can be exploited to create innovative materials with unique properties, such as advanced polymers, catalysts, or other functional materials for various industrial applications.

InChI:InChI=1/C5H6BrNO2/c6-3-1-2-4(8)7-5(3)9/h3H,1-2H2,(H,7,8,9)

Synthetic route

piperidine-2,6-dione (1121-89-7) → 3-bromopiperidine-2,6-dione (62595-74-8)

Conditions	Yield
With bromine In chloroform at 110℃; for 1.5h;	99%
With bromine In chloroform at 20 - 110℃; for 1.5h; Inert atmosphere; Sealed tube;	55%
With bromine In chloroform at 113℃; for 1.5h; Sealed tube;	54.5%

4-nitroisoindoline + 3-bromopiperidine-2,6-dione (62595-74-8) → 3-(4-nitro-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione

Conditions	Yield
With copper(l) iodide; potassium carbonate In tetrahydrofuran at 60℃; for 6h; Reagent/catalyst; Solvent; Temperature;	90.4%
In N,N-dimethyl-formamide at 100℃; for 20h; Solvent; Temperature;	73.1%

3-bromopiperidine-2,6-dione (62595-74-8) + (3-aminophenyl)carbamic acid tert-butyl ester (68621-88-5) → tert-butyl N-[3-[(2,6-dioxo-3-piperidyl)amino]phenyl]carbamate

Conditions	Yield
With sodium hydrogencarbonate In N,N-dimethyl-formamide at 80℃; for 16h;	84.2%
In N,N-dimethyl-formamide at 80℃; for 12h;

3-bromopiperidine-2,6-dione (62595-74-8) + benzyl-methyl-amine (103-67-3) → 3-(benzyl-methyl-amino)-piperidine-2,6-dione

Conditions	Yield
In N,N-dimethyl-formamide at 20℃; for 16h;	83%
In tetrahydrofuran at 72℃; for 16h;

1-methyl-piperazine (109-01-3) + 3-bromopiperidine-2,6-dione (62595-74-8) → 3-(4-methylpiperazin-1-yl)piperidine-2,6-dione

Conditions	Yield
at 20℃; for 2h;	82%

3-bromopiperidine-2,6-dione (62595-74-8) → 3-azidopiperidine-2,6-dione

Conditions	Yield
With sodium azide In water; acetone at 20℃; for 24h; Inert atmosphere;	80%
With sodium azide In acetone at 20℃; for 48h;	1.44g

3-bromopiperidine-2,6-dione (62595-74-8) + C25H26F2N4O3 → C30H31F2N5O5

Conditions	Yield
Stage #1: C25H26F2N4O3 With sodium hydride In tetrahydrofuran; mineral oil at 0 - 20℃; for 0.25h; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil for 1h;	78.41%

2-Phenyl-4,5,6,7-tetrahydro-4,7-dithia-1,3-indandion (7747-10-6) + 3-bromopiperidine-2,6-dione (62595-74-8) → 3-<2-(1,3-Dioxo-2-phenyl-4,5,6,7-tetrahydro-4,7-dithiaindanyl)>glutarimid (76059-14-8)

Conditions	Yield
With sodium 1.) EtOH, 2.) THF, reflux, 1 h;	78%

3-bromopiperidine-2,6-dione (62595-74-8) + C27H30N4O3 → tert-butyl 7-[4-[[1-(2,6-dioxo-3-piperidyl)-2-oxobenzo[cd]indol-6-yl]methyl]pyrazol-1-yl]-4-azaspiro[2.5]octane-4-carboxylate

Conditions	Yield
Stage #1: C27H30N4O3 With sodium hydride In tetrahydrofuran; mineral oil at 0 - 20℃; for 0.25h; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil	75.67%

3-bromopiperidine-2,6-dione (62595-74-8) + 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (1745-07-9) → 3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)piperidine-2,6-dione

Conditions	Yield
at 20℃; for 18h;	75%

3-bromopiperidine-2,6-dione (62595-74-8) + tert-butyl 4-[4-[1-(2-oxo-1H-benzo[cd]indol-6-yl)cyclopropyl]pyrazol-1-yl]piperidine-1-carboxylate → tert-butyl 4-[4-[1-[1-(2,6-dioxo-3-piperidyl)-2-oxobenzo[cd]indol-6-yl]cyclopropyl]pyrazol-1-yl]piperidine-1-carboxylate

Conditions	Yield
Stage #1: tert-butyl 4-[4-[1-(2-oxo-1H-benzo[cd]indol-6-yl)cyclopropyl]pyrazol-1-yl]piperidine-1-carboxylate With sodium hydride In tetrahydrofuran; mineral oil at 20℃; for 0.166667h; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil	74.71%

3-bromopiperidine-2,6-dione (62595-74-8) + C26H31N3O → 3-(6-((1-((1r,4r)-4-neopentylcyclohexyl)-1H-pyrazol-4-yl)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione

Conditions	Yield
Stage #1: C26H31N3O With sodium hydride In tetrahydrofuran; mineral oil at 25℃; for 3.5h; Stage #2: 3-bromopiperidine-2,6-dione In mineral oil	71.98%

3-bromopiperidine-2,6-dione (62595-74-8) + tert-butyl 4-[4-[(2-oxo-1H-benzo[cd]indol-6-yl)methyl]phenyl]piperazine-1-carboxylate → tert-butyl 4-[4-[[1-(2,6-dioxo-3-piperidyl)-2-oxobenzo[cd]indol-6-yl]methyl]phenyl]piperazine-1-carboxylate

Conditions	Yield
Stage #1: tert-butyl 4-[4-[(2-oxo-1H-benzo[cd]indol-6-yl)methyl]phenyl]piperazine-1-carboxylate With sodium hydride In tetrahydrofuran; mineral oil at 0℃; for 0.25h; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil at 60℃; for 0.5h;	70.37%

3-bromopiperidine-2,6-dione (62595-74-8) + 2,2'-disulfanediyldiisonicotinamide → 2-((2,6-dioxopiperidin-3-yl)thio)isonicotinamide

Conditions	Yield
Stage #1: 2,2'-disulfanediyldiisonicotinamide With potassium carbonate; sodium thiosulfate In N,N-dimethyl-formamide at 20℃; for 1h; Stage #2: 3-bromopiperidine-2,6-dione In N,N-dimethyl-formamide at 20℃; for 2h;	69.2%

3-bromopiperidine-2,6-dione (62595-74-8) + 3-Bromothiophenol (6320-01-0) → 3-((3-bromophenyl)thio)piperidine-2,6-dione

Conditions	Yield
With caesium carbonate In acetonitrile at 20℃; for 2h;	67.1%

3-bromopiperidine-2,6-dione (62595-74-8) + tert-butyl 4-(5-chloro-6-oxo-1,6-dihydropyridazin-4-yl)piperazine-1-carboxylate → tert-butyl 4-(5-chloro-1-(2,6-dioxopiperidin-3-yl)-6-oxo-1,6-dihydropyridazin-4-yl)piperazine-1-carboxylate

Conditions	Yield
With potassium carbonate In dimethyl sulfoxide for 48h;	67%

1,2,3,4-tetrahydroisoquinoline (91-21-4) + 3-bromopiperidine-2,6-dione (62595-74-8) → 3-(3,4-dihydroisoquinolin-2(1H)-yl)piperidine-2,6-dione

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 72℃; for 1.5h;	66%

1,2,3,4-tetrahydroisoquinoline (91-21-4) + 3-bromopiperidine-2,6-dione (62595-74-8) → 3-(isoindolin-2-yl)piperidine-2,6-dione

Conditions	Yield
In tetrahydrofuran at 72℃; for 14h;	66%

3-bromopiperidine-2,6-dione (62595-74-8) + thiophenol (108-98-5) → 3-(phenylthio)piperidine-2,6-dione

Conditions	Yield
With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 1h;	66%

3-bromopiperidine-2,6-dione (62595-74-8) + 1-cyclopropyl-1H-benzo[d]imidazole-2-thiol → 3-((1-cyclopropyl-1H-benzo[d]imidazol-2-yl)thio)piperidine-2,6-dione

Conditions	Yield
With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 0.5h;	65.6%

3-bromopiperidine-2,6-dione (62595-74-8) + 3-fluoro-4-(4-(4-((2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)benzyl)piperazin-1-yl)benzonitrile → 4-(4-(4-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile

Conditions	Yield
Stage #1: 3-fluoro-4-(4-(4-((2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)benzyl)piperazin-1-yl)benzonitrile With sodium hydride In tetrahydrofuran; mineral oil at 0 - 20℃; for 0.25h; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil	63%

3-bromopiperidine-2,6-dione (62595-74-8) + 7-chloro-1,2,3,4-tetrahydro-isoquinoline (82771-60-6) → 3-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)piperidine-2,6-dione

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 16h;	62%

3-bromopiperidine-2,6-dione (62595-74-8) + C27H30N4O3 → C32H35N5O5

Conditions	Yield
Stage #1: C27H30N4O3 With sodium hydride In tetrahydrofuran; mineral oil at 0 - 20℃; for 0.25h; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil	61%

3-bromopiperidine-2,6-dione (62595-74-8) + di-tert-butyl dicarbonate (24424-99-5) + 6-fluoro-3-nitroaniline (369-36-8) → 3-((3-amino-4-fluorophenyl)amino)piperidine-2,6-dione

Conditions	Yield
Stage #1: di-tert-butyl dicarbonate; 6-fluoro-3-nitroaniline With dmap In tetrahydrofuran at 50℃; for 12h; Inert atmosphere; Stage #2: With palladium/alumina; hydrogen In methanol at 15℃; under 2585.81 Torr; for 2h; Stage #3: 3-bromopiperidine-2,6-dione Further stages;	60.6%

3-bromopiperidine-2,6-dione (62595-74-8) + C27H23FN6O → 4-[4-[[1-[[1-(2,6-dioxo-3-piperidyl)-2-oxobenzo[cd]indol-6-yl]methyl]pyrazol-4-yl]methyl]piperazin-1-yl]-3-fluorobenzonitrile

Conditions	Yield
Stage #1: C27H23FN6O With sodium hydride In tetrahydrofuran; mineral oil at 5 - 20℃; for 0.25h; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil	60.5%

4-(4-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (149377-19-5) + 3-bromopiperidine-2,6-dione (62595-74-8) → tert-butyl 4-[4-[(2,6-dioxo-3-piperidyl)oxy]phenyl]piperidine-1-carboxylate

Conditions	Yield
With sodium hydride In N,N-dimethyl-formamide at 90℃; for 12h; Inert atmosphere;	60%

3-bromopiperidine-2,6-dione (62595-74-8) + 6-[[4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)phenyl]methyl]-1H-benzo[cd]indol-2-one → 3-[6-[[4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)phenyl]methyl]-2-oxobenzo[cd]indol-1-yl]piperidine-2,6-dione

Conditions	Yield
Stage #1: 6-[[4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)phenyl]methyl]-1H-benzo[cd]indol-2-one With sodium hydride In tetrahydrofuran; mineral oil at 0 - 20℃; Stage #2: 3-bromopiperidine-2,6-dione In tetrahydrofuran; mineral oil at 20 - 70℃;	59.59%

3-bromopiperidine-2,6-dione (62595-74-8) + monothiophthalimide (18138-18-6) → 3-(3-oxo-2,3-dihydroisoindol-1-ylidene)piperidine-2,6-dione

Conditions	Yield
With potassium carbonate In tetrahydrofuran for 7h; Eschenmoser coupling reaction; Heating;	58%
With sodium carbonate In tetrahydrofuran for 7h; Eschenmoser coupling; Heating / reflux;	58%

3-bromopiperidine-2,6-dione (62595-74-8) + C26H31N3O → 3-(6-((1-((1s,4s)-4-neopentylcyclohexyl)-1H-pyrazol-4-yl)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione

Conditions	Yield
Stage #1: C26H31N3O With sodium hydride In tetrahydrofuran; mineral oil at 25℃; for 0.166667h; Stage #2: 3-bromopiperidine-2,6-dione In mineral oil	57.48%

3-bromopiperidine-2,6-dione (62595-74-8) + 1-ethyl-1H-benzo[d]imidazole-2-thiol (39573-31-4) → 3-((1-ethyl-1H-benzo[d]imidazol-2-yl)thio)piperidine-2,6-dione

Conditions	Yield
With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 0.5h;	57.3%

Upstream product

• 1121-89-7 piperidine-2,6-dione 

Downstream Products

• 16477-31-9 3-(2,3-Dihydro-1,1-dioxido-3-oxo-1,2-benzisothiazol-2-yl)-2,6-dioxopiperidine 
• 76059-14-8 3-<2-(1,3-Dioxo-2-phenyl-4,5,6,7-tetrahydro-4,7-dithiaindanyl)>glutarimid 
• 74972-59-1 3-(2-methyl-1,3-dioxo-1H-inden-2-yl)piperidine-2,6-dione 
• 76059-13-7 3-<2-(1,3-Dioxo-2-phenylindanyl)>glutarimid 
• 477728-23-7 C₁₈H₁₇NO₂S 
• 870806-30-7 3-(2-aminobenzylamino)piperidine-2,6-dione 
• 730240-80-9 3-(2-chlorobenzylamino)-piperidine-2,6-dione 
• 1174737-83-7 2-(4-hydroxyphenyl)-6,7-dihydro[1,3]thiazolo[4,5-b]pyridin-5(4H)-one 
• 1004763-36-3 2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-b]pyridine 
• 351432-17-2 3-(benzylamino)piperidine-2,6-dione 

Relevant academic research and scientific papers

Synthesis of 1,2,3-triazole ‘click’ analogues of thalidomide

Click analogues of thalidomide were prepared from 3-azidoglutarimide and a diverse array of arylacetylenes and N-ethynyl/N-propargyl phthalimide derivatives. The sequence necessitated a new and scalable synthesis of the key click intermediate 3-azidoglutarimide. The dipolar cycloaddition reactions between the azidoglutarimide and the alkynyl coupling partners utilized a copper sulfate/sodium ascorbate reagent system in aqueous tetrahydrofuran and were first explored using substituted arylalkynes. Along with the click analogues of thalidomide, the click counterparts of the teratogenic and antiangiogenic thalidomide analogue EM-12 were prepared.

CRBN LIGANDS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PROTEIN DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

CRBN LIGANDS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula (1) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.